Loading…
Loading…
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
Investors need to pay close attention to ALG stock based on the movements in the options market lately.
Alamo Group (NYSE: ALG - Get Free Report) and AB SKF (OTCMKTS:SKFRY - Get Free Report) are both industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent
Shares of Alamo Group, Inc. (NYSE: ALG - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong
SEGUIN, Texas, October 1, 2026 /PRNewswire/ -- Alamo Group Inc. (NYSE: ALG) announced today that its Board of Directors has declared its quarterly dividend of $0.34 per share. Payment of the October dividend will be made on October 28, 2026, to shareholders of record at the close of business on October 15, 2026.
Alamo Group (NYSE: ALG - Get Free Report) and Timken (NYSE: TKR - Get Free Report) are both mid-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk. Dividends Alamo Group pays an annual dividend of
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), who maintain rights in Greater China.
Deere, Kubota, CNH, AGCO and Alamo have been highlighted in this Industry Outlook article.